Perspectives of immune checkpoint ligand expression : regulation and clinical implication
|Name: Sang-Jun Ha ( firstname.lastname@example.org )|
|2019-present||Affiliate Faculty, POSTECH|
|2019-present||Professor, Yonsei University|
|2014-2019||Associate Professor, Yonsei University|
|2009-2014||Assistant Professor, Yonsei University|
|2007-2009||Research Associate, Emory University School of Medicine, USA|
|2004-2007||Postdoctoral fellow, Emory University School of Medicine, USA|
|2001-2004||Postdoctoral fellow, POSTECH|
|1998-2001||Ph.D., Division of Molecular and Life Sciences, POSTECH|
Perspectives of immune checkpoint ligand expression
: regulation and clinical implication
In tumor microenvironment, expression of immune checkpoint ligands (ICLs) is prerequisite to trigger the inhibitory signal via immune checkpoint receptors (ICRs). Although ICL expression frequently occurs in tumor cell-intrinsic manner, extrinsic factors derived from tumor microenvironment can fine-tune ICL expression by tumor cells or prompt non-tumor cells, including immune cells, to express ICLs. Considering extensive interaction between T cells and other immune cells within tumor microenvironment, ICL expression on immune cells can be as significant as ICLs on tumor cells in anti-tumor immune responses. Here we introduce factors, which contribute to induction of ICLs in either tumor cells or immune cells, and concise mechanisms relevant to their induction.
BMB Rep 2021 Jun 3;5347. Online ahead of print.